

allows inducible expression of ROR $\gamma$  upon addition of doxycycline. Upon its induction ROR $\gamma$  binds to the RORE in the luciferase reporter plasmid and induces luciferase. This system can be used to identify ROR $\gamma$  antagonists. This system has been tested successfully in 1536-well plate high throughput analysis.

**Potential Commercial Applications:** Identification of therapeutic compounds to treat asthma, inflammation, and various autoimmune diseases such as osteoarthritis, multiple sclerosis.

**Competitive Advantages:** Novel and unique system to screen and identify chemical and drugs for their ROR $\gamma$  antagonistic activity.

**Development Stage:**

- Early-stage.
- Pre-clinical.
- In vitro data available.

**Inventors:** Drs. Yukimasa Takeda and Anton M. Jetten (NIEHS).

**Publications:**

1. Jetten AM. Retinoid-related receptors (RORs): Critical roles in development, immunity, circadian rhythm, and cellular metabolism. *Nucl Recept Signal*. 2009;7:1–32. [PMID: 19381306].

2. Yang XO, *et al.* T helper 17 lineage differentiation is programmed by orphan receptors ROR alpha and ROR gamma. *Immunity* 2008 Jan;28(1):29–39. [PMID: 18164222].

3. Kurebayashi S, *et al.* Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. *Proc Natl Acad Sci USA*. 2000 Aug 29;97(18):10132–10137. [PMID:10963675].

**Intellectual Property:** HHS Reference No. 253–2010/0—Research Tool. Patent protection is not being pursued for this technology.

**Related Technology:** HHS Reference No. E–222–2009/0—RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses (Dr. Anton M. Jetten, NIEHS).

**Licensing Contact:** Suryanarayana (Sury) Vepa, PhD; 301–435–5020; [vepas@mail.nih.gov](mailto:vepas@mail.nih.gov).

**Collaborative Research Opportunity:** The NIEHS, Laboratory of Respiratory Biology, Cell Biology Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize retinoid-related orphan receptors (RORs) function in chronic diseases. For collaboration opportunities, please contact Elizabeth M. Denholm, PhD at [denholme@niehs.nih.gov](mailto:denholme@niehs.nih.gov).

Dated: July 27, 2011.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2011–19817 Filed 8–3–11; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, August 2, 2011, 9 a.m. to August 2, 2011, 3 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 which was published in the **Federal Register** on July 20, 2011, 76FFRN43333–43334.

The meeting has been rescheduled for August 23, 2011. The time and meeting location remain the same. The meeting is closed to the public.

Dated: July 29, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011–19813 Filed 8–3–11; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Heart, Lung, and Blood Institute Special Emphasis Panel, Training Grant Review.

**Date:** August 24, 2011.

**Time:** 10:30 a.m. to 4:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

**Contact Person:** Roy L. White, PhD, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7176, Bethesda, MD 20892–7924, 301–435–0310, [whiterl@nhlbi.nih.gov](mailto:whiterl@nhlbi.nih.gov).

**Name of Committee:** National Heart, Lung, and Blood Institute Special Emphasis Panel, Ancillary Studies Review.

**Date:** August 26, 2011.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

**Contact Person:** Tony L. Creazzo, PhD, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7180, Bethesda, MD 20892–7924, 301–435–0725, [creazzotl@mail.nih.gov](mailto:creazzotl@mail.nih.gov).

**Name of Committee:** National Heart, Lung, and Blood Institute Special Emphasis Panel, Research Dissemination and Implementation Grants.

**Date:** August 26, 2011.

**Time:** 1 p.m. to 4 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

**Contact Person:** Keith A. Mintzer, PhD, Scientific Review Officer, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7186, Bethesda, MD 20892–7924, 301–435–0280, [mintzerk@nhlbi.nih.gov](mailto:mintzerk@nhlbi.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: July 29, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011–19796 Filed 8–3–11; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections